top of page
iPharmaCenter
For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com
US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension
The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca’s New Drug Application (NDA) for baxdrostat under Priority Review , marking a key regulatory milestone for patients with hard‑to‑control or treatment‑resistant hypertension. The application seeks approval for baxdrostat as an add‑on therapy to existing antihypertensive treatments in adult patients whose blood pressure remains inadequately controlled despite standard care. Also read: Top 10 pharmaceutical c
Novartis’ Fabhalta Demonstrates Improved Hemoglobin Levels in PNH Patients Switching from Anti-C5 Therapy | iPharmaCenter
Novartis has announced positive results from the Phase IIIB APPULSE-PNH study, highlighting the effectiveness of Fabhalta (iptacopan), an...
Hypertension | News | Updates | iPharmaCenter
Janssen Pharmaceutical has updated the Phase 3 MACiTEPH study, which evaluates macitentan 75mg in patients with Chronic Thromboembolic...
Coronary Artery Disease | News | Blogs | Updates
Bayer presented the long-term studies of Xarelto in patients with coronary artery disease and/or peripheral artery disease. Bayer has...
bottom of page